Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.

Coronavirus Infection Clinical Trial

— Ruxo-Sim-20  

Official title:

Randomized Phase II Clinical Trial of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.Ruxo-Sim-20 Clinical Trial.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04348695
• Other study ID #: Ruxo-Sim-20
• Secondary ID: 2020-001405-23
• Status: Completed
• Phase: Phase 2
• Start date: April 12, 2020
• Est. completion date: January 31, 2021

Study information

• Verified date: June 2022
• Source: Fundación de investigación HM
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

COVID-19's mechanism to enter the cell is initiated by its interaction with its cellular receptor, the angiotensin-converting enzyme. As a result of this union, a clathrin-mediated endocytosis process begins. This route is one of the therapeutic targets for which available drugs are being investigated in order to treat COVID-19 infection. This is one of the mechanisms blocked by drugs like ruxolitinib and chloroquine.

Various drugs approved for clinical use that block the clathrin-mediated endocytosis pathway have been explored. It has been found that the best in vitro and in vivo results were obtained with statins, which also allowed generating a greater potent adaptive immune response.

Therefore, statins and specifically simvastatin make it possible to block the entry process used by COVID-19, block inflammation by various mechanisms and increase the adaptive immune response. All of these processes are desirable in patients infected with COVID-19.

Statins have been proposed to have beneficial effects in patients infected with MERS-COV, another coronavirus similar to COVID-19, but there have been no randomized studies supporting the use of statins in patients with COVID-19 infection.

In this project we propose the combined use of one of these drugs, ruxolitinib with simvastatin, looking for a synergistic effect in the inhibition of viral entry and in the anti-inflammatory effect.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 94
• Est. completion date: January 31, 2021
• Est. primary completion date: January 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients who have given their written informed consent. If it is considered that obtaining written consent could constitute a factor for the transmission of the disease (given the high contagiousness of the SARS-Cov-2 virus), it will be permitted to obtain duly justified verbal consent in the patient's medical history.

• Clinical diagnosis or confirmed by analytical tests (PCR of viral RNA or detection of antiSARS-Cov-2 antibodies) that requires care in hospital and that are grade 3 or 4 of the WHO 7-point ordinal scale of severity categorization for COVID.

• Platelets> 50,000 / uL, neutrophils> 500 / ul

• Kidney or liver failure is not a contraindication, dose adjustment will be made according to the SmPC

• Women of childbearing potential who are sexually active, not undergoing a hysterectomy or double adnexectomy, should follow the following indications for contraception:

• Negative serum or urine pregnancy test in the 72 hours prior to the start of treatment.

• Use of a medically accepted contraceptive method during: 2 months prior to the start of study treatment, during the study and up to 3 months after the last dose of treatment.

Exclusion Criteria:

• Documented concomitant severe bacterial or fungal infection

• Infection with HIV, HCV, HBV

• Age <18 years

• Thrombocytopenia <50,000 / uL, Neutropenia <500 / uL

• Women of childbearing age who do not use an effective contraceptive method.

• Pregnant or lactating women.

• Patients who do not want or cannot comply with the protocol.

• Patients with impaired gastrointestinal function or gastric disease that significantly impairs the absorption of ruxolitinib or simvastatin, such as: severe ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, extensive resection (> 1m) of the small intestine or inability to swallow oral medication. Previous partial or total gastrectomy is not an exclusion criterion

Related Conditions & MeSH terms

• Coronavirus Infection
• Coronavirus Infections
• COVID-19
• Respiratory Insufficiency

Intervention

Drug:
• Ruxolitinib plus simvastatin
Ruxolitinib 5 mg orally every 12 hours for 7 days, which will be increased to 10 mg every 12 hours for a total of 14 days. Simvastatin 40 mg orally every 24 hours for 14 days

Other:
• Standard of Care
Patients will receive treatment according to usual clinical practice in the participant site.

Locations

Country	Name	City	State
Spain	Hospital Universitario Madrid Sanchinarro	Madrid

Sponsors (2)

Lead Sponsor	Collaborator
Fundación de investigación HM	Apices Soluciones S.L.

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of patients who develop severe respiratory failure.	Patients achieving a grade 5 or higher of the WHO 7-point ordinal scale of severity categorization for COVID at day 7 from randomization.	7 days
Secondary	Percentage of patients who develop severe respiratory failure.	Patients achieving a grade 5 or higher of the WHO 7-point ordinal scale of severity categorization for COVID at day 14 from randomization.	14 days
Secondary	Length of ICU stay.	Time from ICU admision to ICU discharge.	28 days
Secondary	Length of hospital stay	Time from hospital admision to hospital discharge.	28 days
Secondary	Survival rate at 6 months	Percentage of patients alive at 6 months	6 months
Secondary	Survival rate at 12 months	Percentage of patients alive at 12 months	12 months
Secondary	Survival rate at 28 days	Percentage of patients who died from any cause 28 days after inclusion in the study	28 days
Secondary	Percentage of patients with each AE by grade	Percentage of patients with each AE by grade in relation with total number of treated patients	28 days
Secondary	Percentage of patients who discontinued due to AEs	Percentage of patients who discontinued due to AEs in relation with total number of treated patients	28 days